Description
General description
A hydroxamate-based inhibitor of matrix metalloproteinases and TACE (TNF-α convertase; ADAM17). Inhibits the activation-dependent shedding of L-selectin from neutrophils, eosinophils, and lymphocytes as well as phenylarsine oxide (PAO)-induced shedding in neutrophils. Also blocks the shedding of several cell surface proteins such as pro-TGF-α, IL-6 receptor α-subunit, and β-amyloid precursor protein. Reported to inhibit TNF-α release and impart protection against aspirin-induced gastric mucosal injury. Acts as a weak inhibitor of angiotensin converting enzyme (IC₅₀ = 18 µM).
Biochem/physiol Actions
Cell permeable: no
Primary Target
MMPs
Product does not compete with ATP.
Reversible: no
Target IC₅₀: 18 µM against angiotensin converting enzyme
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Bennett, T.A., et al. 2000. J. Immunol.164, 4120.
Fiorucci, S., et al. 1998. Aliment. Pharmacol. Ther.12, 1139.
Hooper, N.M., et al. 1997. Biochem. J.321, 265.
Parvathy, S., et al. 1997. Biochem. J. 327, 37.
Arribas, J., et al. 1996. J. Biol. Chem.271, 11376.
Legal Information
Manufactured exclusively by Peptides International, Louisville, Kentucky, USA.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
